It can be difficult to assess whether it is worthwhile to pursue a potential analysis project or what options are genuinely available. For example:
- Can the results from your latest RCT be compared to earlier studies using a different endpoint?
- Is there a credible adjustment mechanism that can be applied?
- Do our RCT and Real World evidence plans conform to the TPP?
- What is missing from making a cogent health economic argument?
- What study and analysis options exist to fill them (advantages/disadvantages)?
- Is there anything else we can squeeze out from all the different data sources we have in our possession (RCT’s, claims database, longitudinal and cross-sectional observational studies, market research studies)?
Knowledge of study design, statistical/health economic modelling and market access/payer insights are all crucial to answering such questions with confidence. We can review a host of published manuscripts from a technical perspective to draw out implications for your product.
Our reports detail the options and make recommendations. We cannot guarantee quick fixes (but at least in such circumstances our reports will justify why this is the case). Our findings can be used in many ways – recently as input to an international Payer Advisory Board.